Active, not recruitingPhase 2NCT05686551
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
Studying Huntington disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Tominersen(drug)
- Enrollment
- 301 enrolled
- Eligibility
- 25-50 years · All sexes
- Timeline
- 2023 – 2026
Study locations (20)
- Uab Medicine, Birmingham, Alabama, United States
- Barrow Neurological Institute, Phoenix, Arizona, United States
- University of California Davis Medical System, Sacramento, California, United States
- CenExel Rocky Mountain Clinical Research, LLC, Englewood, Colorado, United States
- Georgetown University, Washington D.C., District of Columbia, United States
- University of Florida, Gainesville, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- John Hopkins University School of Medicine, Baltimore, Maryland, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- Dent Neurological Institute, Amherst, New York, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05686551 on ClinicalTrials.govOther trials for Huntington disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07513844Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's DiseaseFirst Affiliated Hospital of Fujian Medical University
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07537075An Extension of SKY-0515 in Participants With Huntington's DiseaseSkyhawk Therapeutics, Inc.
- RECRUITINGPHASE3NCT07326709A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's DiseaseNovartis Pharmaceuticals
- RECRUITINGPHASE1, PHASE2NCT07451613Safety and Tolerability Study of Human Neural Stem Cells for Huntington's DiseaseLeslie Thompson
- RECRUITINGEARLY PHASE1NCT06634628iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009CHDI Foundation, Inc.
- RECRUITINGPHASE2, PHASE3NCT07378644Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's DiseaseSkyhawk Therapeutics, Inc.
- RECRUITINGNCT07253038Evaluation of Three Tests to Assess Social Cognition in Huntington DiseaseRegion Skane
- RECRUITINGNANCT07213648Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)University of Virginia